Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 showing remission in about ...

With a 42% placebo-adjusted reduction in proteinuria at week 36, Vera Therapeutics Inc. met its primary endpoint in the Origin phase III trial with BAFF and APRIL dual inhibitor atacicept in treating ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

An experimental medicine from Vera Therapeutics significantly reduced levels of toxic protein in the urine of patients with ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...